Market access agreements for pharmaceuticals in Europe: diversity of approaches and underlying concepts
<p>Abstract</p> <p>Background</p> <p>Market Access Agreements (MAA) between pharmaceutical industry and health care payers have been proliferating in Europe in the last years. MAA can be simple discounts from the list price or very sophisticated schemes with inarguably...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2011-10-01
|
| Series: | BMC Health Services Research |
| Online Access: | http://www.biomedcentral.com/1472-6963/11/259 |
| _version_ | 1830215457593884672 |
|---|---|
| author | Jarosławski Szymon Toumi Mondher |
| author_facet | Jarosławski Szymon Toumi Mondher |
| author_sort | Jarosławski Szymon |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Background</p> <p>Market Access Agreements (MAA) between pharmaceutical industry and health care payers have been proliferating in Europe in the last years. MAA can be simple discounts from the list price or very sophisticated schemes with inarguably high administrative burden.</p> <p>Discussion</p> <p>We distinguished and defined from the health care payer perspective three kinds of MAA: Commercial Agreements (CA), Payment for Performance Agreements (P4P) and Coverage with Evidence Development (CED). Apart from CA, the agreements assumed collection and analysis of real-life health outcomes data, either from a cohort of patients (CED) or on per patient basis (P4P). We argue that while P4P aim at reducing drug cost to payers without a systematic approach to addressing uncertainty about drugs' value, CED were implemented provisionally to reduce payer's uncertainty about value of a medicine within a defined time period.</p> <p>Summary</p> <p>We are of opinion that while CA and P4P have a potential to reduce payers' expenditure on costly drugs while maintaining a high list price, CED address initial uncertainty related to assessing the real-life value of new drugs and enable a final HTA recommendation or reimbursement and pricing decisions. Further, we suggest that real cost to health care payers of drugs in CA and P4P should be made publicly available in a systematic manner, to avoid a perverse impact of these MAA types on the international reference pricing system.</p> |
| first_indexed | 2024-12-18T06:56:23Z |
| format | Article |
| id | doaj.art-d262c86b66ce4e1f88218b5ed1a56d2d |
| institution | Directory Open Access Journal |
| issn | 1472-6963 |
| language | English |
| last_indexed | 2024-12-18T06:56:23Z |
| publishDate | 2011-10-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Health Services Research |
| spelling | doaj.art-d262c86b66ce4e1f88218b5ed1a56d2d2022-12-21T21:17:10ZengBMCBMC Health Services Research1472-69632011-10-0111125910.1186/1472-6963-11-259Market access agreements for pharmaceuticals in Europe: diversity of approaches and underlying conceptsJarosławski SzymonToumi Mondher<p>Abstract</p> <p>Background</p> <p>Market Access Agreements (MAA) between pharmaceutical industry and health care payers have been proliferating in Europe in the last years. MAA can be simple discounts from the list price or very sophisticated schemes with inarguably high administrative burden.</p> <p>Discussion</p> <p>We distinguished and defined from the health care payer perspective three kinds of MAA: Commercial Agreements (CA), Payment for Performance Agreements (P4P) and Coverage with Evidence Development (CED). Apart from CA, the agreements assumed collection and analysis of real-life health outcomes data, either from a cohort of patients (CED) or on per patient basis (P4P). We argue that while P4P aim at reducing drug cost to payers without a systematic approach to addressing uncertainty about drugs' value, CED were implemented provisionally to reduce payer's uncertainty about value of a medicine within a defined time period.</p> <p>Summary</p> <p>We are of opinion that while CA and P4P have a potential to reduce payers' expenditure on costly drugs while maintaining a high list price, CED address initial uncertainty related to assessing the real-life value of new drugs and enable a final HTA recommendation or reimbursement and pricing decisions. Further, we suggest that real cost to health care payers of drugs in CA and P4P should be made publicly available in a systematic manner, to avoid a perverse impact of these MAA types on the international reference pricing system.</p>http://www.biomedcentral.com/1472-6963/11/259 |
| spellingShingle | Jarosławski Szymon Toumi Mondher Market access agreements for pharmaceuticals in Europe: diversity of approaches and underlying concepts BMC Health Services Research |
| title | Market access agreements for pharmaceuticals in Europe: diversity of approaches and underlying concepts |
| title_full | Market access agreements for pharmaceuticals in Europe: diversity of approaches and underlying concepts |
| title_fullStr | Market access agreements for pharmaceuticals in Europe: diversity of approaches and underlying concepts |
| title_full_unstemmed | Market access agreements for pharmaceuticals in Europe: diversity of approaches and underlying concepts |
| title_short | Market access agreements for pharmaceuticals in Europe: diversity of approaches and underlying concepts |
| title_sort | market access agreements for pharmaceuticals in europe diversity of approaches and underlying concepts |
| url | http://www.biomedcentral.com/1472-6963/11/259 |
| work_keys_str_mv | AT jarosławskiszymon marketaccessagreementsforpharmaceuticalsineuropediversityofapproachesandunderlyingconcepts AT toumimondher marketaccessagreementsforpharmaceuticalsineuropediversityofapproachesandunderlyingconcepts |